Background {#Sec1}
==========

Computerized physician order entry (CPOE) with medication-related clinical decision support (CDS) is an effective solution to reduce drug-related problems and pharmacist workload (Hammar et al. [@CR5]; Claus et al. [@CR4]). Most medication-related decision support functions, such as dosage checking and drug--drug interaction (DDI) checking, are typically implemented by a set of computerized drug alerting rules. One major problem faced by drug alerting rules is the alert fatigue (Nanji et al. [@CR6]), which is usually caused by highly exhaustive and sensitive rules. Recent related work shows override rates can be as high as 53.6% (Nanji et al. [@CR6]), 87.6% (Topaz et al. [@CR10]), and 93% (Bryant et al. [@CR2]) respectively. To address this issue, lots of work has been focused on constructing minimized and concise drug rule sets. For example, Shah et al. ([@CR9]) built a tiered medication knowledge subset from a commercial knowledge base. The subset contains clinical significant drug contraindications, and only interrupts physicians for severe alerts. Phansalkar et al. ([@CR7]) developed a minimum set of 15 high-severity, clinically significant DDIs from several commercial knowledge bases. Classen et al. ([@CR3]) identified 7 most common DDIs by reviewing multiple sources. The public DDI knowledge base SFINX (Swedish, Finnish, INteraction X-referencing) tiers DDIs according to clinical significance (A-D), which enables threshold settings for automated warnings (Andersson et al. [@CR1]).

Aim of the study {#Sec2}
================

The aim of this study to build and evaluate a concise rule set suitable for Chinese hospitals. Compared to existing related work, this rule set not only covers the western medicine, but also includes various Chinese patent medicine (CPM) that is extensively used by Chinese hospitals. For example, a typical Chinese hospital (DaYi Hospital, ShanXi Province, China) uses 1981 drugs, and 462 (23.3%) are Chinese patent medicine.

Ethical approval {#Sec3}
----------------

This study was approved by the medical ethics committee of DaYi Hospital. All collected data have been de-identified by the information department of the hospital.

Methods {#Sec4}
=======

Settings and materials {#Sec5}
----------------------

DaYi Hospital was established in 2011 and is the largest general hospital (2600-bed) in ShanXi Province, China. Until 2013, all the drug checking work in DaYi was performed manually by clinical pharmacists. At the drug dispensing time, the pharmacists would inspect medication orders submitted by the physicians. Unqualified orders would be returned to physicians and recorded by the pharmacists. The recorded medication errors between 2011 and 2013 were used to analyze the most frequent and error-prone drug rules. These records are the initial resource for building the concise rule set.

In 2013, we initiated the KTP (Knowledge Translation Platform) project (Zhang et al. [@CR11]). One of KTP's goals is to build a medication-related CDS for CPOE, in order to help pharmacists reduce work load and assist the drug checking process. At the beginning of KTP, a preliminary question is: whether to develop own medication-related CDS or use a commercial one. Although there are already mature commercial products on the Chinese market, e.g. Wolters Kluwer/Medicom PASS (Prescription Automatic Screening System), we have our own considerations for not choosing such off-the-shelf systems. (1) Although the rule base of commercial products may be much more comprehensive and detailed, it is still necessary to tier and routinely tailor the complete rule set to suit local hospital situations. For pharmacists, there is not much workload advantage over maintaining a local-developed rule set. (2) From the perspective of the KTP project, the pharmaceutical knowledge is an inseparable part of the entire knowledge base. Inside the KTP knowledge base, there are semantic relations between drug and other medical entities. For example, many clinical rules (e.g. *if \[Use of Aspirin\]* == *true \|\| \[Use of Clopidogrel\]* == *true, recommend \[INR monitor\]*) and clinical treatment protocols (predefined order sets or clinical pathways) involves drug entities. If using third-party products, even if the vendors open their knowledge base or provide external access interfaces, the integration and interaction between different systems (e.g. mapping of drug entities across systems) can be complex and effort-taking. Therefore, we decided to develop an own system.

Information model {#Sec6}
-----------------

To implement a computerized rule set, an information model of drug alerting rules is designed (Fig. [1](#Fig1){ref-type="fig"}). It defines 11 rule types (Table [1](#Tab1){ref-type="table"}), including dosage (single intake), daily dosage (accumulated intake), administration route, frequency, skin test, dissolvent, dissolvent dosage, DDI, contra-indication, and prescription restriction.Fig. 1The Information model for drug alerting rules Table 1Drug alerting rule typesRule typeDescriptionExampleDosageDefines maximum dosage for one medical orderMaximum dosage of Ambroxol injection is 2 doses\
\[Dosage\] ≤ 2 dosesDaily dosageDefines maximum daily accumulated dosageMaximum daily dosage of ShuXueNing injection (Ginkgo biloba extract) is 4 doses\
\[DailyDosage\] ≤ 4 dosesAdministration routeDefines allowed administration routeCobamamide injection should be administrated by intramuscular injection\
\[AdministrationRoute\] = {intramuscular}FrequencyDefines allowed frequencyCeftriaxone injection frequency should be qd. (1/day)\
\[Frequency\] = {qd}skin testDefines whether skin test flag should be specified in the medication order, so as to remind the nursesLidocaine hydrochloride injection needs skin test\
\[SkinTest\] = trueDissolventDefines allowed dissolventDissolvent for pHGF injection can only be 10% glucose injection\
\[Dissolvent\] = {10% glucose}Dissolvent dosageDefines maximum dissolvent dosageDissolvent dosage for iron sucrose injection is 100 ml\
100 ml ≤ \[DissolventDosage\] ≤ 100 mlPregnancy riskAssigns each drug to FDA pregnancy category, which contains five categories: ABCDX. Category X should never be applied to pregnant patientsFDA pregnancy category of Ribavirin is X\
\[PregancyRiskLevel\] = XDrug-drug interaction (DDI)Defines synergistic, antagonistic, etc. interactions between drugsWarfarin and Vitamin K have antagonistic interaction\
Interaction (Warfarin, Vitamin K)Contra-indicationDefines drug-disease and drug-symptom conflictsClopidogrel cannot be used against patients with active peptic ulcer\
\[Contra-indication\] = "\[active peptic ulcer\] == false && \[gastrointestinal hemorrhage\] == false", check passed if result is trueprescription restrictionRestricts the prescription of certain drugs for some departments or physiciansFor third-line antibiotics such as Vancomycin, only chief physicians have prescription rights. Pediatrics departments cannot prescribe Vancomycin\
\[RestrictedDeptment\] = {pediatrics}, \[RestrictedPhyscian\] = {ID1, ID2,...}

These rule types are designed according to pharmacists' drug checking requirements. However, there are also other rule types, such as personalized dosing algorithms (e.g. children or elder patients with different body weights and body surface areas, or patients with renal insufficiency based on creatinine clearance). In the current development phase, we haven't supported such rules because they require lots of patient context data, such as body weight, body surface area, Crcl rate, etc. These data mostly reside in heterogeneous formats in external systems, such as HIS (Hospital Information System), LIS (Laboratory Information System), EMR (Electronic Medical Record), etc. How to extract high-quality and well-structured data in expected formats from various sources is a non-trivial task. In the next development phase, we will try to solve this data acquisition problem and support more rule types.

Authoring tool {#Sec7}
--------------

Based on the above information model, the database schema for drug alerting rules can be decided, and a corresponding rule authoring tool has been developed (Fig. [2](#Fig2){ref-type="fig"}). The tool was developed as a web-based application. Fig. 2Drug alerting rule authoring tool. **a** Main page for editing drug rules. The *left panel* is the drug list, where user can click one to edit. On the *right side* is the edit area, which contains three tab pages: basic info, interactions and contraindications. Basic info tab page defines basic rules such as skin test, dosage, etc. **b** Tab page for editing drug--drug interactions. Users can select drugs that have interactions with the current one. **c** Tab page for editing contraindication rules. *Left panel* is the context item (e.g. lab test, symptoms, vital signs, etc.) list used to define contraindicated conditions. The *right side* is a table of user-selected context items, and a graphical rule composer, as well as a textual rule expression editor

Results {#Sec8}
=======

Drug alerting rule set {#Sec9}
----------------------

Based on the recorded medication errors between 2011 and 2013, the pharmacists used the rule authoring tool to define a rule set that was able to cover the most widely used and error-prone drugs. The first version of the rule set was created in June 2013, and contained 150 drugs. The detailed rule set is provided in "[Appendix](#Sec14){ref-type="sec"}".

Medication-related CDS based on the rule set {#Sec10}
--------------------------------------------

With the rule set, a medication-related clinical decision support was developed and integrated into CPOE (Fig. [3](#Fig3){ref-type="fig"}). Reasoning of the rules is executed by a home-grown rule engine (refer to <http://ktp.brahma.top/Display/TestRuleEngine>, <http://ktp.brahma.top/Pages/Evaluation/RuleEngine/Index.html>). The CPOE was also developed by our research team, under the product name "MIAS (Medical Information Automation System)". The interaction between CPOE and CDS was implemented by web services. Whenever the physician submits orders, CPOE will call the drug checking web service of CDS to trigger the rule engine. CDS-detected alerts are then returned to CPOE, and CPOE displays them to the physician as warnings (Fig. [3](#Fig3){ref-type="fig"}b). The physician can either cancel order submission or override the alert. All detected alerts are also sent to the notification area (Fig. [3](#Fig3){ref-type="fig"}a) for review. In exceptional cases due to patient status, physicians may state their reasons for overriding the alert. While reviewing the drug alerts, physicians can use infobutton (Fig. [3](#Fig3){ref-type="fig"}c) to retrieve related drug labels (Fig. [3](#Fig3){ref-type="fig"}d). For pharmacists, we provide a backend web portal for viewing the status (accepted or overridden) and override reason for each alert. The information flow of drug alert status is automatically directed and tracked by the system, which has greatly reduced the necessity of face-to-face communication and telephone calls between physicians and pharmacists. Fig. 3Medication-related clinical decision support in CPOE. **a** Notification area for drug alerts. User can review and process all triggered drug alerts in this area. **b** Drug alert message. **c** Infobutton for drug labels. **d** Retrieved drug label by Infobutton

In this system, only physicians have the right to change the status of an alert (accept or override). Pharmacist only have read-only rights for alert statuses, but they can edit (increase threshold or change rule content) or deactivate corresponding rules if they found many occurrences of an unreasonable alert.

Evaluation of the rule set in CPOE {#Sec11}
----------------------------------

The computerized rule set was first implemented in the inpatient CPOE on 2013/12/25 (The outpatient CPOE was provided by another vendor, and had not been integrated with our system). Until now, the system has been used in 49 inpatient departments for more than 2 years. In order to evaluate the actual effect of the rule set, system log data between 2013/12/25 and 2015/07/01 were collected. During this period, totally 68,182 inpatient visits were enrolled into the system and 2,747,140 medication orders were submitted.

For the submitted medication errors, totally 18,666 alerts were detected by the CDS, and 2803 alerts were overridden by physicians. Therefore, the overall override rate is 15.0% (2803/18,666), and accept rate is 85%. Among the 18,666 alerts, Chinese patent medicine (CPM) takes up 38.4% (7168 in 18,666).

According to Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, several results caught our attention and we further analyzed these results.Table 2Drug alert analysisDrug nameDrug name (Chinese)Alert typeAlertsOverridden alertsOverride rate (%)Ambroxol injection氨溴索注射液Daily dosage4938220.4Salvia TMP injection丹参川芎嗪注射液Daily dosage403900.0Injection esomeprazole注射用埃索美拉唑Dissolvent dosage1261123998.3Thin Chi glycopeptide injection薄芝糖肽注射液Daily dosage105020.2Shuxuening injection舒血宁注射液Daily dosage87600.0Fufangkushen injection复方苦参注射液Daily dosage76140.5Lidocaine hydrochloride injection盐酸利多卡因注射液Skin test69128741.5Injection cefathiamidine注射用头孢硫脒Daily dosage48800.0Injection thymopentin注射用胸腺五肽Administration route41327767.1Calcium gluconate injection葡萄糖酸钙注射液Dissolvent30700.0Iron sucrose injection蔗糖铁注射液Dissolvent dosage29800.0Injection ambroxol注射用氨溴索Administration route24800.0Injection aminophylline氨茶碱注射液Dissolvent22916170.3Injection pantoprazole注射用泮托拉唑Dissolvent dosage21911150.7Yinxingdamo injection银杏达莫注射液Dissolvent dosage20310250.2Injection omeprazole注射用奥美拉唑Administration route19819196.5Injection pantoprazole注射用泮托拉唑Administration route1334634.6Injection of fat-soluble vitamins II注射用脂溶性维生素IIDissolvent131107.6Ceftriaxone for injection注射用头孢曲松Frequency1165648.3Injection cefamandole ester注射用头孢孟多酯Prescription restriction11300.0Injection pancreatic kallikrein注射用胰激肽原酶Administration route11300.0Leucovorin injection亚叶酸钙注射液Administration route11200.0Injection cefoxitin注射用头孢西丁Prescription restriction11000.0Injection omeprazole注射用奥美拉唑Dissolvent dosage1036159.2Oxytocin injection缩宫素注射液Dissolvent9600.0Heparin sodium injection肝素钠注射液Administration route9100.0Sodium for injection cefodizime注射用头孢地嗪钠Prescription restriction8700.0Alprostadil injection前列地尔注射液Administration route802835.0Furosemide injection呋塞米注射液Dissolvent705172.9Injection esomeprazole注射用埃索美拉唑Frequency6000.0Salvia TMP injection丹参川芎嗪注射液Dissolvent dosage5700.0Injectable piperacillin sodium and tazobactam sodium注射用哌拉西林钠他唑巴坦钠Prescription restriction5300.0Cefoperazone sulbactam注射用头孢哌酮舒巴坦Prescription restriction5100.0Kangai injection康艾注射液Dissolvent dosage4700.0Leucovorin injection亚叶酸钙注射液Frequency4300.0Levofloxacin injection左氧氟沙星注射液Dissolvent dosage382155.3Injection torasemide注射用托拉塞米Frequency3800.0Large plants Rhodiola injection大株红景天注射液Dissolvent dosage3700.0Cefoperazone注射用头孢哌酮Prescription restriction3600.0Xuebijing injection血必净注射液Dissolvent dosage362672.2Injection of fat-soluble vitamins II注射用脂溶性维生素IIDaily dosage3339.1Ceftazidime for injection注射用头孢他啶Prescription restriction3000.0Injection imipenem cilastatin sodium注射用亚胺培南西司他丁钠Prescription restriction2800.0Sodium for injection aescinate注射用七叶皂苷钠Daily dosage24312.5Torasemide injection托拉塞米注射液Frequency2300.0Shuxuening injection舒血宁注射液Dissolvent211781.0Injection of water-soluble vitamins注射用水溶性维生素Dosage2100.0Amiodarone injection胺碘酮注射液Dissolvent201575.0Injection ulinastatin注射用乌司他丁Frequency2000.0Meropenem for injection注射用美罗培南Prescription restriction1900.0Polyene phosphatidylcholine injection多烯磷脂酰胆碱注射液Dissolvent191157.9Injection pantoprazole注射用泮托拉唑Dissolvent18844.4Insulin injection胰岛素注射液DDI17317.6Fluconazole injection氟康唑注射液Prescription restriction1600.0Injection esomeprazole注射用埃索美拉唑Dosage1500.0Sodium for injection aescinate注射用七叶皂苷钠Dosage1500.0Vancomycin injection注射用万古霉素Prescription restriction1400.0Vitamin C injection维生素C注射液DDI13323.1Injection omeprazole注射用奥美拉唑Dissolvent131292.3Methylprednisolone sodium succinate injection注射用甲泼尼龙琥珀酸钠DDI1119.1Injection carbazochrome sodium sulfonate注射用卡络磺钠Dissolvent11763.6Itraconazole oral solution伊曲康唑口服液Prescription restriction1000.0Fufangkushen injection复方苦参注射液Dosage1000.0Flurbiprofen injection氟比洛芬酯注射液Dosage1000.0Injection lentinan注射用香菇多糖Dosage1000.0Other low occurrence drug alerts (i.e. fired alert count \<10)1552516.1Total18,666280315.0 Table 3drug alert analysis grouped by rule typesAlert typeAlertsOverridden alertsOverride rate (%)Daily dosage12,212340.3Dissolvent dosage2299156067.9Administration route139154239.0Dissolvent96431232.4Skin test69128741.5Prescription restriction59500.0Frequency3005618.7Dosage15153.3DDI63711.1Total18,666280315.0 Among the detected alerts, "daily dosage" rule type has the highest alert occurrence rate (12,212 alerts in total 18,666). We dived into the "daily dosage" alerts, and found four of the top five drugs are CPM, i.e. "Salvia TMP injection (4039 alerts)", "Thin Chi glycopeptide injection (1050 alerts)", "Shuxuening injection (876 alerts)" and "Fufangkushen Injection (761 alerts)", which are responsible for the majority of "daily dosage" alerts. CPM is mostly extracted or manufactured from Chinese traditional herbs. Compared to western synthesized chemical medicine, though herbs take much longer time to take effect, they also have fewer side effects and adverse reactions. In fact, CPM usually plays an auxiliary or supportive role in treatment regimens. For this reason, some physicians relaxed their vigilance and didn't pay enough attention when using CPM. This also explains why CPM has a noticeable percentage in all the detected alerts (38.4%).The "dissolvent dosage" rule type has the highest override rate (67.9%). The 67.9% override rate is remarkably high compared to other rule types, which means about 2/3 "dissolvent dosage" alerts have been overridden. We consulted with the clinical pharmacists, and found many alerts were related to patients with certain conditions, e.g. renal deficiency or heart failure. For such patients, it is reasonable to use smaller dosage than required by the drug fact sheet. Such false-positive cases have added up to the overridden alerts. To address this issue, we are currently considering using more patient context data to exclude such false-positive alerts.The "skin test" rule type has the second highest override rate (41.5%). Investigation reveals that this high override rate is caused by the discrepancy in physicians' understanding of the "skin test" rule. In this system, the skin test rule is not designed as a mandatory requirement for the current specific patient, but a general risk reminder for nurses. That means, if there is potential allergic risk (either from medical literature or drug fact sheet) for a certain drug, physicians should set the skin test flag for corresponding medication orders. If not, the skin test rule will give an alert. When it comes to the drug administrating phase, the nurses will investigate this flag as well as patient's specific conditions (e.g. known allergy history towards certain drugs) to judge whether skin test is needed. However, many physicians treated the "skin test" rule as patient-specific flags, i.e. if a certain drug has potential allergic risk, but the physician already knows the current patient is not allergic to this drug, he/she will not set the flag and override the skin test alert.

Besides the above analysis for certain rule types, there are also high alert occurrence and override rates for several individual drugs, which are caused by different reasons and need case-by-case investigation. Base on these periodical retrospective analyses, pharmacists can continually improve the rule set (e.g. change threshold, revise rule content, deactivate rules) to better suit clinical use.

Discussion {#Sec12}
==========

The primary contribution of this study is a concise drug alerting rule set oriented to Chinese hospitals. As the rule set was built based on the historical data from a large-scale (2600-bed) general hospital with high patient throughput (e.g. 68,182 inpatient visits from 2013/12/25 to 2015/07/01), the rule set should be able to reflect the medication use profile of large populations and may serve as a reference for other Chinese hospitals.

In this study, the computerized rule set can be used as a "preliminary screening tool" against physicians' medication orders. In DaYi Hospital, pharmacists need to check 4968 medication orders per day on average, and unqualified orders have to be returned to physicians. This is a time-consuming and laborious work. With the drug alerting CDS, many potential mistakes can be ruled out before they reach the final checkpoint of pharmacists. According to the evaluation result, physicians have revised 85% of detected medication orders. In the long run, the system will not only alleviate the workload of pharmacists (many drug use errors can be revised by the physicians without pharmacists' intervention) but also enhance the workflow efficiency (avoid the "reject-revise-resubmit" process).

This study has several limitations or arguments:The proposed rule set is not suitable for procedural drug rules. For example, the preparation of azithromycin solution is a multi-step procedure. First, azithromycin is dissolved with sterilized water to formulate into 0.1 g/ml. Then, add it to 250--500 ml 0.9% NaCl or 5% glucose solution to get a 1.0--2.0 mg/ml concentration. This procedural logic cannot be easily represented as a single succinct dissolvent rule.The current rule set doesn't support complex personalized dosing algorithms. In certain contexts, such as children or elder patients with different body weights and body surface areas, or patients with renal insufficiency based on creatinine clearance, more complicated personalized dosing algorithms are needed. To support them, the information model needs further extension to represent such individualized knowledge.DDI rule subtyping. In current system implementation, all DDI rules are treated as one rule type. However, it's better to design more DDI sub-types in order to achieve more fine-grained alerts. For example, the SFINX project (Andersson et al. [@CR1]) tiers DDIs according to clinical significance (A--D), which enables fine-grained threshold settings for automated warnings.Lack of complete evaluation. In this study, the accept and override rates can be easily calculated from the log data. However, it is not so easy to calculate accuracy and specificity, which requires reviewing every overridden alert in order to identify true positives and false positives. In the future, we will build a "closed-looped" alert tracking workflow, in which the state changes (either by physicians or pharmacists) and change reasons (e.g. why physician override an alert, and why pharmacists reject overriding an alert) of each alert are tracked and logged by the system.Use of clinically identified ADEs. ADEs (adverse drug events) are valuable data for analyzing drug use and medication-related CDS. In China, we have a multi-level ADE reporting mechanism. Level I: Physicians submit detected ADE and related clinical data (patient demographics, symptoms, drug use info, etc.) to the hospital's pharmacy department. Level 2: Pharmacists submit confirmed ADEs to drug regulatory authorities, i.e. China SFDA (a counterpart of US FDA). Level 3: China SFDA evaluates drug risks based on nation-wide collected ADEs. Although this ADE-reporting mechanism is well designed, it's a sad reality that it hasn't lived up to its maximum benefit, largely due to the wide-spread under-reporting problems. Most ADE events were concealed or neglected in daily practices, and the few reported ADEs cannot be used as a solid and complete data source for analyzing physicians' drug use and evaluating our rule set. To address this issue, we are currently cooperating with clinical pharmacists to detect unreported ADEs from clinical documents (e.g. patient daily progress notes) by natural language processing (NLP) technologies.Coverage of the rule set. One basic assumption of this study is that drug alerts conform to Pareto-alike distribution, where small portion of drug rules accounts for the majority of alerts. As a supporting case, one US study in 2005 (Reichley et al. [@CR8]) used a commercial drug alerting rule set. It contains 48,262 rules for 1537 drugs, but 90% of alerts are focused on 58 drugs. From their daily work experience, the pharmacists in DaYi hospital also hold the same opinion that small set of drugs generate majority of errors. However, to further verify this assumption, a further evaluation is needed to get the coverage rate of the rule set. This requires a full set for all drugs on the Chinese market, and a parallel comparison of the full set and concise set on a large-scale and long-term patient drug use data set. A coverage rate greater than 80% should be ideal. Otherwise, more rules may have to be added to the rule set.Another problem of the rule set is how to keep up with the latest clinical evidence. Occasionally published guidelines or case reports will necessitate adding or revising rules. For example, the China SFDA (State Food and Drug Administration) periodically publish ADE (adverse drug events) reports collected all round the country. A well-maintained rule set should keep up with these public sources. Currently, our research team is developing a semi-automatic program based on NLP, which will help pharmacists extract structured contents from the public ADE reports.

Generally speaking, the overall 85.0% accept rate indicates the rule set has been well received by physicians \[compared to the override rates reported in other recent studies, e.g. 53.6% (Nanji et al. [@CR6]), 87.6% (Topaz et al. [@CR10])\] and is effective in reducing pharmacists' workload. Moreover, the pharmacists are continually analyzing (i.e. analyze those drug alerts with high override rates), improving (e.g. raise alert threshold to reduce false positive alerts) and expanding (i.e. add more drugs and rules) the drug rule set, which will further improve its accuracy and coverage. However, due to the various complex and individualized patient statuses, such a computerized rule set is never meant to substitute the routine work of pharmacists, but can be used an effective supportive tool.

Conclusions {#Sec13}
===========

In this study, a concise drug alerting rule set for Chinese hospitals was constructed by pharmacists. The case study in a Chinese hospital indicates the medication-related CDS based on the rule set has been well received by physicians. For other hospitals, they may use this rule set as a starter kit for building their own medication-related CDS systems or use it to tier commercial rule bases.

Appendix {#Sec14}
========

See Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}.Table 4Drug rule set (Part 1)DrugDrug (Chinese name)Rule contentRule typeCompound matrine injection^a^复方苦参注射液^a^2--3 doseDosageInjection aescinate^a^注射用七叶皂苷钠^a^10--20 mgDosageInjection of Ginkgo biloba extract^a^银杏叶提取物注射液^a^≤4 doseDosageSalvia ligustrazine injection^a^丹参川芎嗪注射液^a^≤2 doseDosageAmbroxol injection盐酸氨溴索注射液≤2 doseDosagePhosphate sodium for injection磷酸钠注射液≤2 doseDosageThin chi glycopeptide injection^a^薄芝糖肽注射液^a^≤2 doseDosageCiticoline injection胞二磷胆碱注射液≤2 doseDosageTiopronin injection硫普罗宁注射液≤2 doseDosageInjection cefathiamidine注射用头孢硫脒≤1 doseDosageShuXueNing injection^a^舒血宁注射液^a^≤2 doseDosageInjection esomeprazole注射用埃索美拉唑20--40 mgDosageFlurbiprofen injection氟比洛芬酯注射液50 mgDosageInjection lentinan注射用香菇多糖1 mgDosageHydrocortisone injection氢化可的松注射液50--100 mgDosageXiaoaiping injection^a^消癌平注射液^a^2--4 mlDosageCalcium gluconate injection葡萄糖酸钙注射液1--2 gDosageSodium phosphate injection注射用磷酸肌酸钠≤1 doseDosageJavanica oil emulsion injection^a^鸦胆子油乳注射液^a^10--30 mlDosageInjection ulinastatin注射用乌司他丁100,000UDosageInjection of Ginkgo biloba extract^a^银杏叶提取物注射液^a^5 doseDaily dosageCompound matrine injection^a^复方苦参注射液^a^3 doseDaily dosageSalvia ligustrazine injection^a^丹参川芎嗪注射液^a^2 doseDaily dosageAmbroxol injection盐酸氨溴索注射液2 doseDaily dosagePhosphate sodium for injection磷酸钠注射2 doseDaily dosageThin chi glycopeptide injection^a^薄芝糖肽注射液^a^2 doseDaily dosageCiticoline injection胞(二)磷胆碱注射液2 doseDaily dosageTiopronin injection硫普罗宁注射液2 doseDaily dosageInjection aescinate^a^注射用七叶皂苷钠^a^20 mgDaily dosageInjection cefathiamidine头孢硫脒注射液1 doseDaily dosageInjection of fat-soluble vitamins I注射脂溶性维生素I1 doseDaily dosageInjection of fat-soluble vitamins II注射脂溶性维生素II1 doseDaily dosageInjection of water-soluble vitamins注射用水溶性维生素1 doseDaily dosageL-carnitine injection左旋肉碱注射液Iv pushAdministration routeOmeprazole injection (Losec)奥美拉唑注射液 (罗塞克)Iv pushAdministration routeOmeprazole injection (AoXiKang, Luoren)奥美拉唑注射液 (奥西康,罗润)Iv dripAdministration routeInjection thymopentin注射用胸腺五肽Intramuscular injection, subcutaneous injectionAdministration routeInjection cobamamide注射用腺苷钴胺Intramuscular injectionAdministration routeAmbroxol injection盐酸氨溴索注射液IvAdministration routeFurosemide injection呋塞米注射液IvAdministration routePantoprazole injection注射用泮托拉唑Iv dripAdministration routePancreatic kininogenase for injection注射用胰激肽原酶Intramuscular injectionadministration routeLeucovorin injection亚叶酸钙注射液Iv dripAdministration routeL-carnitine injection左卡尼汀注射液IvAdministration routeHeparin sodium injection肝素钠注射液Subcutaneous injection, ivAdministration routeAlprostadil injection前列地尔注射液IvAdministration routeCeftriaxone for injection头孢曲松钠注射液1/dayFrequencyInjection esomeprazole注射用埃索美拉唑1/day, 1/12 hFrequencyLeucovorin injection亚叶酸钙注射液1/day, 1/6 hFrequencyInjection torasemide注射用托拉塞米1/dayFrequencyTorasemide injection托拉塞米注射液1/dayFrequencyInjection ulinastatin注射用乌司他丁1--3/dayFrequencyLidocaine hydrochloride injection盐酸利多卡因注射液Skin test requiredSkin TestFurosemide injection呋塞米注射液NaCl, sterile waterDissolventSodium heparin injection肝素钠注射液NaCl, sterile waterDissolventBrain carnosine injection脑肌肽注射液NaCl, 5% glucoseDissolventTanreqing injection^a^痰热清注射液^a^NaCl, 5% glucoseDissolventPantoprazole injection注射用泮托拉唑NaClDissolventInjection carbazochrome sodium sulfonate注射用卡络磺钠NaClDissolventEdaravone injection依达拉奉注射液NaClDissolventLipoic acid injection硫辛酸注射液NaClDissolventXuebijing injection^a^血必净注射液^a^NaClDissolventIron sucrose injection蔗糖铁注射液NaClDissolventInjection of fat-soluble vitamins I注射脂溶性维生素IGlucose, sterile waterDissolventInjection of fat-soluble vitamins II注射脂溶性维生素IIGlucose, sterile waterDissolventPaclitaxel liposome for injection紫杉醇脂质体注射液Glucose, sterile waterDissolventInjection of liposomal amphotericin B注射用两性霉素B脂质体Glucose, sterile waterDissolventPolyene phosphatidylcholine injections多烯磷脂酰胆碱注射液Glucose, sterile waterDissolventInjection breviscapine^a^注射用灯盏花素^a^5% glucose, 10% glucose, 0.9% NaClDissolventAminophylline injection氨茶碱注射液GlucoseDissolventInjection of Ginkgo biloba extract^a^银杏叶提取物注射液^a^GlucoseDissolventAmiodarone injection胺碘酮注射液5% glucoseDissolventInjection pHGF注射用促肝细胞生长素10% glucoseDissolventGinkgo leaf extract and dipyridamole injection^a^银杏达莫注射液^a^0.9% NaCl, 5% glucose, 10% glucoseDissolventOmeprazole injection奥美拉唑注射液0.9% NaClDissolventCalcium gluconate injection葡萄糖酸钙注射液10% glucoseDissolventOxytocin injection缩宫素注射液NaCIDissolventTanReQing injection^a^痰热清注射液5% glucoseDissolventShuXueNing injection^a^舒血宁注射液^a^5% glucoseDissolventGinkgo leaf extract and dipyridamole Injection^a^银杏达莫注射液^a^500 mlDissolvent dosageLevofloxacin左氧氟沙星250 mlDissolvent dosagePantoprazole injection注射用泮托拉唑100 mlDissolvent dosageXuebijing injection^a^血必净注射液^a^100 mlDissolvent dosageIron sucrose injection蔗糖铁注射液≤100 mlDissolvent dosageInjection esomeprazole注射用埃索美拉唑100 mlDissolvent dosageOmeprazole injection奥美拉唑注射液100 mlDissolvent dosageSalvia ligustrazine injection^a^丹参川芎嗪注射液^a^250--500 mlDissolvent dosageLarge plants Rhodiola injection^a^大株红景天注射液^a^250 mlDissolvent dosageTriazolam tablets三唑仑片FDA pregnancy category X---use on pregnant women is forbiddenPregnancy riskRibavirin利巴韦林Pregnancy riskEstradiolvalerate戊酸雌二醇片Pregnancy riskFluorouracil Injection氟尿嘧啶注射液Pregnancy riskMisoprostol tablets米索前列醇片Pregnancy riskSimvastatin辛伐他汀Pregnancy riskAvi A capsules阿维A胶囊Pregnancy riskEstazolam tablets艾司唑仑片Pregnancy riskBicalutamide tablets比卡鲁胺片Pregnancy riskGoserelin acetate sustained-release implants醋酸戈舍瑞林缓释植入剂pregnancy riskFinasteride tablets非那雄胺片Pregnancy riskFluvastatin氟伐他汀Pregnancy riskFluorouracil implants氟尿嘧啶植入剂Pregnancy riskMifepristone misoprostol tablets米非司酮米索前列醇片Pregnancy riskLevonorgestrel左炔诺孕酮Pregnancy riskEstradiol雌二醇Pregnancy riskInjection cefamandole ester注射用头孢孟多酯Restricted antibiotics. Only chief physicians and above have the prescription right. Resident physicians cannot directly prescribe these drugsPrescription restrictionInjection cefoxitin注射用头孢西丁Prescription restrictionSodium for injection cefodizime注射用头孢地嗪钠Prescription restrictionInjectable piperacillin sodium and tazobactam sodium注射用哌拉西林钠他唑巴坦钠Prescription restrictionCefoperazone sulbactam注射用头孢哌酮舒巴坦Prescription restrictionCefoperazone注射用头孢哌酮Prescription restrictionCeftazidime for injection注射用头孢他啶Prescription restrictionInjection imipenem cilastatin sodium注射用亚胺培南西司他丁钠Prescription restrictionMeropenem for injection注射用美罗培南Prescription restrictionFluconazole injection氟康唑注射液Prescription restrictionVancomycin injection注射用万古霉素Prescription restrictionItraconazole oral solution伊曲康唑口服液Prescription restrictionMinocycline hydrochloride capsules盐酸米诺环素胶囊Prescription restrictionMoxifloxacin injection莫西沙星注射液Prescription restrictionInjectable piperacillin sulbactam注射用哌拉西林舒巴坦Prescription restrictionInjection voriconazole注射用伏立康唑Prescription restrictionAzithromycin for injection注射用阿奇霉素Prescription restrictionInjection caspofungin注射用卡泊芬净Prescription restrictionInjection teicoplanin注射用替考拉宁Prescription restrictionLinezolid injection利奈唑胺注射液Prescription RestrictionMoxifloxacin tablets莫西沙星片Prescription restrictionInjection of amphotericin B liposome注射用两性霉素B脂质体Prescription restriction^a^Chinese patent medicine Table 5Drug rule set (Part 2: DDI pairs)Drug 1Drug 2DescriptionVitamin C injection维生素C注射液Vitamin K1 injection维生素K1注射液Mixture prone to turbidity^a^Four-vitamin injection复方维生素注射液(4)Injection of fat-soluble vitamins I注射脂溶性维生素我Same ingredient. Duplicate therapy^a^Injection of fat-soluble vitamins II注射脂溶性维生素IIMethylprednisolone sodium succinate for injection甲泼尼龙琥珀酸钠注射液Insulin injection胰岛素注射Methylprednisolone sodium succinate for injection increases requirements for insulin or oral hypoglycemic agents in diabetics^a^Methylprednisolone sodium succinate for injection甲泼尼龙琥珀酸钠注射液Recombinant human insulin injection重组人胰岛素注射Methylprednisolone sodium succinate for injection甲泼尼龙琥珀酸钠注射液Protamine recombinant human insulin injection鱼精蛋白重组人胰岛素注射液Salvia ligustrazine injection^b^丹参川芎嗪注射液^b^Vitamin K1 Injection维生素K1注射液Antagnistic effect^a^Ginkgo biloba extract injection银杏叶提取物注射液^b^injection calf blood protein extract注射用小牛血去蛋白提取物Cause serious adverse effects, such as gastrointestinal discomfort, headache, decreased blood pressure, allergic reactionsSelegiline司来吉兰Pseudoephedrine伪麻黄碱MAO inhibitors---Amphetamine and derivativesDiethylpropion二乙胺Fluoxetine氟西汀MAO inhibitors--- selective serotonin reuptake inhibitors (SSRIs)Paroxetine帕罗西汀Citalopram西酞普兰Escitalopram艾司西酞普兰Sertraline舍曲林Fluvoxamine氟伏沙明Duloxetine度洛西汀Venlafaxine文拉法辛Meperidine哌替啶MAO inhibitors---narcotic analgesicsFentanyl芬太尼Tramadol曲马多Amitriptyline阿米替林Selegiline---tricyclic antidepressants (TCAs)Irinotecan伊立替康Clarithromycin克拉霉素Irinotecan---strong CYP3A4 inhibitorsErythromycin红霉素Amiodarone胺碘酮Verapamil维拉帕米Diltiazem地尔硫卓Ketoconazole酮康唑Itraconazole伊曲康唑Fluconazole氟康唑Voriconazole伏立康唑Cimetidine西咪替丁Simvastatin辛伐他汀Clarithromycin克拉霉素HMG Co-A reductase inhibitors---CYP3A4 inhibitorsErythromycin红霉素Amiodarone胺碘酮Verapamil维拉帕米Diltiazem地尔硫卓Ketoconazole酮康唑Itraconazole伊曲康唑Fluconazole氟康唑Voriconazole伏立康唑Roxithromycin罗红霉素Severe DDI reported from literature, including rhabdomyolysis and liver damageErgotamine麦角胺Clarithromycin克拉霉素Ergot alkaloids and derivatives---CYP3A4 inhibitorsErythromycin红霉素Ketoconazole酮康唑Itraconazole伊曲康唑Voreconazole伏立康唑Tizanidine替扎尼定Ciprofloxacin环丙沙星Tizanidine---CYP1A2 inhibitorsFluvoxamine氟伏沙明Mexiletine美西律Propafenone普罗帕酮Amiodarone胺碘酮Zolmitriptan佐米曲普坦Moclobamide吗氯贝胺Triptans---MAO inhibitorsMethylene blue亚甲蓝Chloroquine氯喹QT prolonging agents. Any of two drugs have synergistic effectMoxifloxacin莫西沙星Sotalol索他洛尔Clarithromycin克拉霉素Citalopram西酞普兰Amiodarone胺碘酮Erythromycin红霉素Haloperidol氟哌啶醇Droperidol氟哌利多Domperidone多潘立酮Procainamide普鲁卡因胺Sevoflurane七氟醚Chlorpromazine氯丙嗪Arsenic trioxide白砒Azithromycin阿奇霉素^a^Means these rules are added by the local pharmacists; others are from the work published by other researchers (Phansalkar et al. [@CR7])^b^Chinese patent medicine
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